
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 26, 2010

QUESTCOR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

California
(State or Other Jurisdiction
of Incorporation)

001-14758
(Commission File Number)

33-0476164
(I.R.S. Employer
Identification No.)

3260 Whipple Road Union City, California
(Address of Principal Executive Offices)

94587
(Zip Code)

Registrant's telephone number, including area code: **(510) 400-0700**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**Determination of 2009 Cash Bonuses for Executive Officers**

On February 26, 2010, the Board of Directors (the “Board”) of Questcor Pharmaceuticals, Inc. (the “Company”) approved the 2009 cash bonuses for the Company’s executive officers. The Board determined the 2009 cash bonuses based on its interpretation of each executive officer’s level of satisfaction of the management performance objectives established and tailored for such executive officer by the Compensation Committee for the Company’s 2009 fiscal year. The Board also considered additional subjective and objective criteria in determining each executive officer’s bonus. The table below sets forth the cash bonuses for the following executive officers:

| Name | Title | 2009 Cash Bonus |
|------------------------------|--|-----------------|
| Don M. Bailey | President and Chief Executive Officer | \$301,665 |
| Stephen L. Cartt | Executive Vice President and Chief Business Officer | \$170,170 |
| David J. Medeiros | Senior Vice President, Pharmaceutical Operations | \$129,285 |
| Gary M. Sawka | Senior Vice President, Finance and Chief Financial Officer | \$ 99,450 |
| David Young, Pharm.D., Ph.D. | Chief Scientific Officer | N/A(1) |
| Jason Zielonka, M.D. | Chief Medical Officer | N/A(2) |

(1) Dr. Young commenced employment with the Company on October 30, 2009.

(2) Dr. Zielonka commenced employment with the Company on February 16, 2010.

Determination of 2010 Cash Bonus Target Levels for Executive Officers

On February 26, 2010, the Board approved the 2010 cash bonus target levels for the Company’s executive officers. The actual amount of cash bonuses that may be awarded remains subject to the discretion of the Board. The table below sets forth the 2010 target bonus percentages for the following executive officers:

| Name | Title | 2010 Bonus Target(1) |
|------------------------------|--|----------------------|
| Don M. Bailey | President and Chief Executive Officer | 65% |
| Stephen L. Cartt | Executive Vice President and Chief Business Officer | 55% |
| David J. Medeiros | Senior Vice President, Pharmaceutical Operations | 45% |
| Gary M. Sawka | Senior Vice President, Finance and Chief Financial Officer | 45% |
| David Young, Pharm.D., Ph.D. | Chief Scientific Officer | 60% |
| Jason Zielonka, M.D. | Chief Medical Officer | 45% |

(1) Targets are expressed as a percentage of the officer's 2010 base salary.

Grant of Stock Option to Executive Officer

On February 26, 2010, the Board granted to Jason Zielonka, M.D., the Company's recently appointed Chief Medical Officer, an option to purchase 130,000 shares of common stock of the Company at an exercise price of \$4.68 per share, the Company's closing stock price on the grant date. The options vest monthly over 48 months from February 16, 2010, the date which Dr. Zielonka commenced employment subject to a one year cliff, whereby no options vest until the first anniversary of his start date. The options expire ten years following the date of the grant. The vesting of the option is subject to potential acceleration in the event of a change in control of the Company, pursuant to the terms of Dr. Zielonka's Severance Agreement.

SIGNATURES

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 3, 2010

QUESTCOR PHARMACEUTICALS, INC.

By: /s/ Gary M. Sawka
Gary M. Sawka
Senior Vice President, Finance, and Chief Financial
Officer